Human CellExp VEGFR2/Flk-1/KDR, human recombinant protein
KDR, CD309, FLK1, VEGFR, VEGFR2, kinase insert domain receptor
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P35968 |
---|---|
Calculated MW | This protein with 6×his tag at C-terminus, and has a calculated MW of 84.1 kDa. DTT-reduced protein migrates as 100-110 kDa protein due to glycosylation. |
Gene ID | 3791 |
---|---|
Gene Symbol | VEGFR2 |
Other Names | KDR, CD309, FLK1, VEGFR, VEGFR2, kinase insert domain receptor |
Gene Source | Human |
Source | HEK293 cells |
Assay&Purity | SDS-PAGE; ≥95% |
Assay2&Purity2 | N/A; |
Recombinant | Yes |
Results | Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is typically 9-20 ng/ml in the presence of 5 ng/ml rhVEGF165. |
Target/Specificity | VEGFR2 |
Application Notes | Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C. |
Format | Lyophilized |
Storage | -20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Kinase insert domain receptor (KDR) also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF. The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.
References
Jin P.,et al.Arthritis Res. Ther. 10:R73-R73(2008).
Albuquerque R.J.,et al.Nat. Med. 15:1023-1030(2009).
Yin L.Y.,et al.Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases.
Yu Y.,et al.Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
Hillier L.W.,et al.Nature 434:724-731(2005).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.